Capital Planning Advisors’s Charles River Laboratories CRL Stock Holding History

Capital Planning Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-927	Closed	-$251K	–	138
2024 Q1	$251K	Sell	927 -12	-1%	-$2.87K	0.04%	128
2023 Q4	$222K	Buy	+939	New	+$185K	0.04%	125
2022 Q3	–	Sell	-950	Closed	-$203K	–	124
2022 Q2	$203K	Sell	950 -31	-3%	-$7.58K	0.05%	127
2022 Q1	$279K	Buy	981 +31	+3%	+$9.56K	0.06%	133
2021 Q4	$358K	Hold	950	–	–	0.07%	119
2021 Q3	$392K	Hold	950	–	–	0.08%	115
2021 Q2	$351K	Hold	950	–	–	0.07%	116
2021 Q1	$275K	Buy	950 +40	+4%	+$11.1K	0.06%	116
2020 Q4	$227K	Hold	910	–	–	0.06%	119
2020 Q3	$206K	Buy	+910	New	+$189K	0.06%	119

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Capital Planning Advisors's CRL Position: Q2 2024 in Review

Capital Planning Advisors sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 927 shares — an estimated $251K sold.

Capital Planning Advisors first reported a position in CRL in Q3 2020 and held it in 10 quarters. The position peaked at $392K in Q3 2021. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

Capital Planning Advisors reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
Capital Planning Advisors sold 927 Charles River Laboratories shares in Q2 2024, an estimated $251K.
Capital Planning Advisors first reported a position in Charles River Laboratories in Q3 2020 and held it in 10 quarters.
Capital Planning Advisors's Charles River Laboratories position peaked at $392K in Q3 2021.
665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Capital Planning Advisors's 13F filing for Q2 2024, filed 12 Aug 2024.